REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY IN THE SHORT-TERM TREATMENT OF HYPERTENSION WITH ISRADIPINE

被引：18

作者：

SARAGOCA, MA

PORTELA, JE

ABREU, P

PLAVNIK, F

VANNETA, A

AJZEN, H

RAMOS, OL

机构：

[1] Hypertension-Nephrology Division, Escola Paulista de Medicina, CNPq—Brasil and IPEPENHI

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1991年 / 4卷 / 02期

关键词：

LEFT VENTRICULAR HYPERTROPHY; REGRESSION; CALCIUM ANTAGONISTS; ISRADIPINE; HYPERTENSION;

D O I：

10.1093/ajh/4.2.188S

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

This was a study of the effectiveness of isradipine, a calcium antagonist of the dihydropyridine group, in reversing left ventricular hypertrophy (LVH) in patients with mild-to-moderate hypertension. Mean arterial pressure was effectively reduced at 90 days of treatment (from 129.5 +/- 2.0 to 111.5 +/- 2.8 mm Hg; P < .001). The electrocardiographic Romhilt-Estes score for LVH showed early reduction at 45 days of treatment (from 7.1 +/- 0.6 to 5.1 +/- 0.4 points; P < .001), and further diminutions were observed at 90 days of treatment (3.8 +/- 0.4 points; P < .01). The echocardiographically determined left ventricular mass indices confirmed these findings (from 175.0 +/- 8.9 to 141.7 +/- 5.5 and to 124.8 +/- 4.2 g/m2; P < .001) for 45 and 90 days, respectively. The results indicate that isradipine is effective in reducing left ventricular mass and that these reductions are observed early in the course of treatment.

引用

页码：S188 / S190

页数：3

共 16 条

[1]

Tarazi R.C., Sen S., Saragoca M.A., Khairallah P., The multifactorial role of catecholamines in hypertensive cardiachypertrophy, Eur Heart J, 3, pp. 103-110, (1982)

[2]

Frohlich E.D., Reversal of target-organ involvement insystemic hypertension: A pharmacologic experience, AmJ Cardiol, 60, pp. 31-71, (1987)

[3]

Kobayashi K., Tarazi R.C., Effect of nitrendipine on coronary flow and left ventricular hypertrophy of hypertension, Hypertension, 5, pp. II45-II51, (1983)

[4]

Messerli F.H., Nunez B.D., Nunez M.M., Et al., Hypertensionand sudden death. Disparate effects of calcium entryblocker and diuretic therapy on cardiac dysrhythmias, Arch Intern Med, 149, pp. 1263-1267, (1989)

[5]

Drayer J., Hall W.D., Smith V.E., Et al., Effect of the calcium channel blocker nitrendipine on left ventricularmass in patients with hypertension, Clin PharmacolTher, 40, pp. 679-685, (1986)

[6]

Giles T.D., Sander G.E., Roffidal L.C., Et al., Comparison ofnitrendipine and hydrochlorothiazide for systemic hypertension, Am J Cardiol, 60, pp. 103-106, (1987)

[7]

Saragoca M.A., Almeida J.B., Amorim M., Et al., Pumpperformance after regression of cardiac hypertrophy following the treatment with isradipine, J Hypertens, 7, pp. S288-S289, (1989)

[8]

Romhilt D.W., Estes E.H., A point-score system for ECGdiagnosis of left ventricular hypertrophy, Am Heart J, 75, 6, pp. 752-758, (1968)

[9]

Devereux R.B., Detection of left ventricular hypertrophyby M-mode echocardiography, Hypertension, 9, (1987)

[10]

Massie M.B., Tubau J.F., Szlachcic J., O'kelly B.F., Hypertensive heart disease: The critical role of ventricular hypertrophy, J Cardiovasc Pharmacol, 13, pp. S18-S24, (1989)

← 1 2 →